[ET Net News Agency, 2 September 2021] CSPC Pharmaceutical Group Limited (01093) said
the "Oseltamivir Phosphate Capsules (75mg)" developed by CSPC Ouyi Pharmaceutical Co.,
Ltd., a subsidiary of the company, has obtained drug registration approval granted by the
National Medical Products Administration of the People's Republic of China, and is deemed
to have passed the consistency of quality and efficacy evaluation of generic drugs.
Oseltamivir is a selective inhibitor of influenza virus neuraminidase, which can inhibit
the release of virus from infected cells and reduce the spread of influenza A or B viruses
via inhibition of neuraminidase activity of influenza A and B viruses. The product is
indicated for the treatment of influenza A and B in adults and children aged 1 year or
above, and prevention of influenza A and B in adults and adolescents aged 13 years or
above. (RC)